A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.

Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.

The players are vying in the CD19 x CD20 Car-T arena.

The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.

The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.

But the former is paying a fraction of what Merck shelled out for raludotatug.

INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.